Gymnasio, a robot as a virtual personal trainer

A robot that becomes a virtual personal trainer : it's not science fiction, but Gymnasio , a device that uses artificial intelligence to monitor the positions of the human body during training.

The startup behind the project has been funded by three Alumni of Politecnico di Milano and two Alumni of Politecnico di Torino, and is among the winners of Switch2Product, the program that champions innovative solutions on the market, new technologies and new business ideas and is supported by Politecnico and from Polihub.

The team met in Alta Scuola Politecnica, during the entrepreneurial program 'Pioneer' of the School of Entrepreneurship and Innovation (SEI) of Turin in a project in collaboration with Sprint Reply and supervised by Prof. Barbara Caputo (PoliTo), and by Prof. Cesare Alippi (PoliMi).

The objective is twofold: to make safe and personalized training accessible to as many people as possible and to revolutionize the home fitness market, which has had a surge during the pandemic .

Gymnasio
Credits: www.gymnasio.it
Gymnasio
Credits: www.gymnasio.it
HOW DOES GYMNASIO WORKS?

Gymnasio is able, thanks to the 3D camera and artificial intelligence algorithms , to correct movements and posture, manage personal records, track progress and give precise feedback during training.

gymnasio
Credits: www.gymnasio.it

Starting from Pepper , the first version of the device with the appearance of a humanoid robot, the Gymnasio team then modified the device with more compact and accessible forms , ideal for training at home in times of pandemics.

“The pandemic played a fundamental role. We will not be able to replace the empathy of a human: we want to give an alternative that can be purchased by everyone and that can be used at home. " declares to TG1 Daniele Gusmini , Alumnus of Automation Engineering and Control Engineering and CEO and co-founder of the start up.

The product, still in the prototype stage, thanks to its small size can be used anywhere and in the future it will be available on the market thanks to a subscription .

New therapies: a spin-off of Politecnico to treat maculopathy

The Exudative maculopathy is a very common eye desease and represents the first cause of loss of sight for people over 50To treat it, until today, it is necessary to have a frequent cycle of injection, an invasive procedure with a high impact on the life of patients, that often abandon their therapy.

To avoid the premature abandonment of the treatment, a group of researchers of the Department of Chemistry, Materials and Chemical Engineering "Giulio Natta" of Politecnico di Milano in collaboration with the Deparment of clinical and biomedical sciences "Luigi Sacco, ASST Fatebenefratelli-Sacco, Università degli Studi di Milano, it has developed Mag Shella device that with a singular injection is able to release precise doses of medicine in defined intervals.

The device was first created in 2015 from the Phd thesis of Marco Ferronibiomedical engineer of Politenico di Milano. In six years, thanks to the support of Polihub that has incubated MgShellthe spin off which has gained a lot of prizes and investments the technology and the business model were developed.

Credits: Polihub
MAG SHELL: A NEW THERAPEUTIC FRONTIER FOR EXUDATIVE MACULOPATHY

The Mag Shell ocular device is a drug "container" that is inserted, with a single injection, into the eye and releases the active ingredient gradually, thus ensuring greater patient adherence to the therapeutic protocol.

This operation is possible thanks to the conformation of the device itself, which alternates layers of biodegradable materials, consisting of magnesium or its alloys, with drug doses.

materiali biodegradabili, costituiti da magnesio o da sue leghe, a dosi di farmaco.

"Today this means avoiding that 40% of patients who drop out of therapy go blind, it means drastically reducing the social impact that chronic diseases have" explains Ferroni in an interview.

The advantages of this procedure are many: in addition to the reduction of costs and the impact of current drug treatment on maculopathic patients, hospital staff and on healthcare costs, there are promising possibilities for using MagShell in other areas of pharmaceutical application as well.

The device is currently in a preclinical in vitro trial phase and the first animal pilot study will begin soon.

primo studio pilota su animale.

Cover Photo: Polihub

MAP is the magazine of the Alumni of Politecnico di Milano The magazine is your compass to navigate everything that is developing and changing in our University. Below you will find a related article : if you like what you are seeing, support us . You will be able to collect your copy for free.